GL1X · GenesisL1 explorer

MolNFT v1 · #125305 · protein

Crystal structure of iso-citrate dehydrogenase R132H in complex with a novel inhibitor (compound 13A)

5L57 · Isocitrate dehydrogenase [NADP] cytoplasmic: “Crystal structure of iso-citrate dehydrogenase R132H in complex with a novel inhibitor (compound 13A)”. X-ray diffraction, 2 ligands (NDP, 6N3), 7 pockets (best druggability 0.69).…

PDB
5L57
Type
protein
Length
409 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Isocitrate dehydrogenase [NADP] cytoplasmic
EC
1.1.1.42
UniProt
O75874
Ligands
NDP, 6N3
Pockets
7 · best druggability 0.69

Structure

x-ray diffraction · 1 distinct chain · 44% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AIsocitrate dehydrogenase [NADP] cytoplasmic (EC 1.1.1.42)protein40944% helix, 17% strandO75874

Ligands and binding sites

  • NDP · Nadph dihydro-nicotinamide-adenine-dinucleotide phosphate · ligand · chains A
  • 6N3 · (1~{R},5~{S})-3-[6-(3-methylbutoxy)-5-[[(1~{R},3~{S})-5-oxidanyl-2-adamantyl]carbamoyl]pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13280.690.82416N3
22720.610.8041empty
3820.500.8421empty
4620.460.8419empty
51490.440.7624empty

Compared structures

  • 5L57 · Crystal structure of Iso-citrate Dehydrogenase R132H in complex with a novel inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00
  • O75874 · AlphaFold monomer V2.0 prediction for isocitrate dehydrogenase [NADP] cytoplasmic (O75874) · a predicted model of the same protein · chain A against A, TM-score 0.91

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.